Doxazosin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters.
The effect of doxazosin, an alpha-1 adrenergic inhibitor, on atherosclerosis was determined in hyperlipidemic hamsters. Control hamsters fed chow plus 0.05% cholesterol and 10% coconut oil were compared to chow baseline animals, and to those receiving either 10 mg/kg/day doxazosin, or 245 mg/kg/day cholestyramine in the atherogenic diet. During 8 weeks of treatment, plasma lipids, mean arterial pressure (MAP) and heart rate (HR) were measured, then the ascending aortic arch was examined en face. Numbers of subendothelial macrophage-foam cells/mm2 and their average size (microns 2) were determined, and Oil red O staining (micrograms ORO/mm2) was quantitated to estimate lipid accumulation. Ultracentrifugation of control plasma demonstrate that low density lipoprotein (LDL) carried most of the cholesterol, and very low density lipoprotein (VLDL) was rich in triglycerides. Compared to controls, doxazosin and cholestyramine similarly decreased plasma total and LDL plus VLDL cholesterols, and total triglycerides on average by 46%, 61% and 45% respectively. High density lipoprotein cholesterol was unchanged. Doxazosin also reduced MAP by 18% without affecting HR. In all hamsters, foam cells and lipid accumulated in a lesion-prone area characterized by elevated endothelial cell density, and a thick intima of basement membrane-like material layered over "pads" of smooth muscle cells. Compared to controls, doxazosin and cholestyramine uniformly reduced the number of foam cells/mm2, foam cell size and ORO staining on average by 66%, 29% and 56%, respectively. We conclude that doxazosin decreases plasma lipids and inhibits the development of the fatty streak to a similar level as cholestyramine treatment.
Department of Clinical Sciences, University of Lowell, MA 01854.
M C
MC
Kowala
J J
JJ
Nunnari
S K
SK
Durham
R J
RJ
Nicolosi
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000473:pathology*; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000494:pharmacology*; D006224:Cricetinae; D017292:Doxazosin; D006339:Heart Rate / Q000187:drug effects; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008647:Mesocricetus; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D008074:Lipoproteins; D002792:Cholestyramine Resin; D002784:Cholesterol; D017292:Doxazosin; D011224:Prazosin